Novo Nordisk

Healthcare

Viking Therapeutics Soars as Weight-Loss Drug Trial Addresses GLP-1 Weakness

Photo via IMAGO/Ulrich Roth/Newscom

Research has shown the adherence rates of patients on GLP-1 therapies can fall as low as 27% after one year.

2 min read

Photo via Michael Siluk/UCG/Universal Images Group/Newscom

Healthcare

No Mo’ Nordisk: Ozempic Maker Rebrands as Novo, Promises New Culture

The name change arrives with Novo shares down 15% in 2026, despite the propitious launch of the oral version of its obesity drug Wegovy.

2 min read
Photo via Jason Bergman/Sipa USA/Newscom

Healthcare

Novo Nordisk Takes Rival Eli Lilly to Court Over Weight-Loss Ad Claims

The Danish pharma giant alleged Lilly misled consumers with false advertising claims that its weight loss drug is superior to Novo’s.

2 min read
Photo via Robin Utrecht/ANP/Newscom

Semiconductors

ASML Becomes Biggest Company in European History

A share price rally pushed ASML’s market cap to $668 billion on Wednesday, beating a European record set by Novo Nordisk in June 2024.

1 min read

Healthcare

Lilly Follows Upbeat Trials for Cholesterol Shot with $4B M&A Spree

Photo via Spencer Jones/GHI//UCG/Universal Images Group/Newscom

The highest dose of a single injection reduced cholesterol levels by 62% in patients, according to Eli Lilly’s recently published study.

2 min read

Healthcare

GLP-1 Race Heats Up with Positive Test Results for Next-Gen Eli Lilly Drug

Photo via Gado Images/Smith Collection/Gado/Sipa USA/Newscom

Approximately one in eight Americans are taking medications like Ozempic or Wegovy for weight loss, diabetes, heart disease and more.

2 min read

Healthcare

Treatment Advances Position Lilly as Weight-Loss Heavyweight

Photo by JHVEPhoto via iStock

The proliferation of cheaper generic drugs and more competition has already begun to bring down prices on weight-loss treatments.

2 min read

Sign Up for The Daily Upside to Unlock This Article

Sharp news & analysis on finance, economics, and investing.